Zistdaru | زیست دارو

What Zistdaru | زیست دارو does

Zistdaru Danesh (زیست دارو دانش) is an Iranian knowledge-based pharmaceutical company founded in 2005 at the Pharmaceutical Products Technology Development Center of Tehran University of Medical Sciences. The company operates a manufacturing facility in Karaj's Baharestan Industrial Park (Alborz Province) housing five pharmaceutical production lines: bacterial recombinant proteins, mammalian (eukaryotic) cell recombinant proteins, high-risk oral solids, solvent and lyophilized vial filling, and botulinum neurotoxin. Its portfolio spans specialty and orphan drugs across neurology (multiple sclerosis, ALS), oncology (CML, GIST, NSCLC, RCC, hepatocellular carcinoma, mantle cell lymphoma), rare diseases (Wilson's, Gaucher, Niemann-Pick, idiopathic pulmonary fibrosis), dermatology/rheumatology, iron deficiency, and aesthetic drugs. With 73 employees, the company runs an enterprise field-sales go-to-market through a national pharmacy network in Iran and direct export channels, with products registered in at least 15 countries including Russia, Belarus, Iraq, Syria, Lebanon, Pakistan, Sri Lanka, Philippines, Kenya, Cameroon, Nigeria, and several Central Asian states.

The company's technology platform combines recombinant protein production using both bacterial and mammalian expression systems, advanced protein purification, lyophilization, and proprietary botulinum neurotoxin manufacturing. Its value proposition rests on international GMP certifications (EAEU, Kenya, Philippines, Sri Lanka, Iraq), ISO 9001:2015 / ISO 10015 / ISO 17025 / ISO 14001 compliance, and a knowledge-based designation supporting R&D conducted by specialized researchers. Revenue is generated through one-time sales of prescription pharmaceutical products to healthcare providers and export partners, with pricing not publicly disclosed. Distribution follows the formal pharmaceutical supply chain domestically and direct export relationships internationally, supported by medical affairs teams in oncology, neurology, and dermatology that run scientific events, clinical studies, and a patient support nursing unit for adverse event reporting and adherence guidance.

Name

Zistdaru | زیست دارو

Legal name

Zistdaru Danesh Company (زیست دارو دانش)

Website

https://zistdaru.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

51–100 employees

Short description

Zistdaru Danesh is an Iranian knowledge-based pharmaceutical manufacturer of specialty and orphan drugs — including recombinant proteins, monoclonal antibodies, and botulinum toxin — serving patients with MS, ALS, oncology, and rare diseases across Iran and 15 export markets.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industries

Oncology Specialty Pharmaceuticals (HLAIACAA), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Specialty pharmaceuticals
• Biopharmaceutical manufacturing
• Recombinant proteins
• Oncology drugs
• Multiple sclerosis treatments

Headquarters

HQ city

Tehran

HQ country

Iran

HQ region

Middle East

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales (Domestic Iran): Sale of specialty pharmaceutical products through pharmacy networks and hospitals across Iran. Products are distributed through authorized distribution channels to healthcare facilities and patients.
2. International Export Sales: Export of registered pharmaceutical products to countries across Middle East, Africa, Central Asia, and EAEU regions including Iraq, Kenya, Philippines, Sri Lanka, Russia, and other target markets.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Zistdaru Danesh is a knowledge-based pharmaceutical company that develops and manufactures specialty pharmaceutical products, including recombinant biologics, monoclonal antibodies, botulinum toxin, and targeted chemotherapy drugs across five GMP-certified production lines. The company sells its products primarily through a national pharmacy network in Iran and through direct export relationships in over 15 countries across the Middle East, Africa, Central Asia, South/Southeast Asia, and Eastern Europe. Its portfolio focuses on neurology, oncology, rare/orphan diseases, dermatology, and iron deficiency therapeutic areas.

Product overview

Zistdaru Danesh is a knowledge-based pharmaceutical company that develops and manufactures recombinant and chemical pharmaceutical products. The company operates five production lines: recombinant protein production using bacteria, high-risk oral solids (tablets and capsules), solvent and lyophilized vial filling, recombinant protein production using animal cells (eukaryotes), and botulinum neurotoxin production. The product portfolio includes specialized medicines across multiple therapeutic areas: Neurology/MS (ZIFERON, GLATZI, TECZIFUMA, TEBAZIO, ROXIMELLA, Relapzent), Oncology (NITAGXHA, SUNIXHA, FILGRAZY, Lenvaxha, Ruxoxha, IBRUXHA, OSIXHA, SORAXHA, ZIVEK), Orphan Drugs (Zistine, Miglutan, ALSAVA, Pirfenzi), Dermatology-Rheumatology (BARTIXHA), Iron Deficiency (FERRIRISE), and Aesthetic Drugs (Zibonta/Botulinum toxin). The company exports to EAEU countries, Kenya, Philippines, Sri Lanka, and other international markets.

Differentiator

Problem solved

Functional benefit

Products and services

• NITAGXHA (Nilotinib) | نیتاگزا Pharmaceutical product containing nilotinib, a protein-tyrosine kinase inhibitor used for treating Philadelphia chromosome-positive chronic myeloid leukemia (CML) in adults and children over 1 year. Sold through pharmacy networks and export markets.
• SUNIXHA (Sunitinib) | سانیزا Pharmaceutical product containing sunitinib, a protein-tyrosine kinase inhibitor used for treating gastrointestinal stromal tumors (GIST), advanced renal cell carcinoma (RCC), and pancreatic neuroendocrine tumors (pNET).
• FERRIRISE (Ferric carboxymaltose) | فریرایز Injectable iron replacement product containing ferric carboxymaltose for treating iron deficiency anemia in children over 1 year and adults, particularly suitable for patients unresponsive to oral iron or with heart/kidney conditions.
• Zistine (Trientine) | زیستین Pharmaceutical product containing 300mg trientine dihydrochloride per capsule, used for Wilson's disease treatment by helping eliminate excess copper from the body. Orphan drug.
• Miglutan (Miglustat) | میگلوتان Pharmaceutical product containing miglustat, used for treating Gaucher disease type 1 and reducing progressive neurological symptoms in Niemann-Pick type C patients. Orphan drug.
• ZIFERON (Interferon beta-1a) | زیفرون Pharmaceutical product containing 9.6 million IU (300 micrograms) interferon beta-1a per vial, used for reducing relapse frequency and delaying disability onset in multiple sclerosis (MS) patients. Recombinant biologic.
• GLATZI (Glatiramer acetate) | گلتزی Pharmaceutical product containing glatiramer acetate, a synthetic polypeptide used for treating relapsing forms of multiple sclerosis (MS) including CIS, RRMS, and SPMS.
• TECZIFUMA (Dimethyl fumarate) | تکزیفوما Pharmaceutical product containing dimethyl fumarate, activates Nrf2 pathway for treating relapsing forms of multiple sclerosis (MS) including CIS, RRMS, and active SPMS.
• TEBAZIO (Teriflunomide) | تبازیو Pharmaceutical product containing teriflunomide, a dihydroorotate dehydrogenase inhibitor used for treating relapsing forms of multiple sclerosis (MS).
• ROXIMELLA (Delayed-release dimethyl fumarate) | روکسیملا Pharmaceutical product containing diroxyimil fumarate, an enteric-coated capsule that activates Nrf2 pathway for treating relapsing forms of multiple sclerosis (MS).
• ALSAVA (Edaravone) | آلساوا Pharmaceutical product containing edaravone, an antioxidant and free radical scavenger used for treating Amyotrophic Lateral Sclerosis (ALS). Orphan drug.
• Relapzent (Siponimod) | ریلاپزنت Pharmaceutical product containing siponimod, an S1P receptor modulator for treating relapsing forms of multiple sclerosis (MS) including CIS, RRMS, and active SPMS.
• BARTIXHA (Baricitinib) | بارتیزا Pharmaceutical product containing baricitinib, a JAK inhibitor for treating rheumatoid arthritis, COVID-19 in hospitalized patients, and severe alopecia areata.
• FILGRAZY (Filgrastim) | فیلگرازی Pharmaceutical product containing filgrastim (G-CSF), a recombinant protein used for treating oncology-related conditions.
• Lenvaxha (Lenvatinib) | لنوازا Pharmaceutical product containing lenvatinib, a tyrosine kinase inhibitor for treating various cancers.
• Ruxoxha (Ruxolitinib) | روکسوزا Pharmaceutical product containing ruxolitinib, a JAK inhibitor for treating myeloproliferative neoplasms.
• IBRUXHA (Ibrutinib) | ایبروزا Pharmaceutical product containing ibrutinib, a BTK inhibitor for treating mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic graft-versus-host disease (cGVHD).
• OSIXHA (Osimertinib) | اسیزا Pharmaceutical product containing osimertinib, a tyrosine kinase inhibitor for treating EGFR-mutated non-small cell lung cancer.
• SORAXHA (Sorafenib) | سورازا Pharmaceutical product containing sorafenib, a multikinase inhibitor for treating hepatocellular carcinoma (HCC), advanced renal cell carcinoma (RCC), and thyroid cancer.
• Pirfenzi (Pirfenidone) | پیرفنزی Pharmaceutical product containing pirfenidone, an antifibrotic agent for treating idiopathic pulmonary fibrosis (IPF). Orphan drug.
• Bridifast (Sugammadex) | بریدیفست Pharmaceutical product containing sugammadex, a selective relaxant binding agent for reversing neuromuscular blockade induced by rocuronium or vecuronium in surgical procedures.
• ZIVEK (Imatinib) | زیوک Pharmaceutical product containing imatinib (as mesylate), a tyrosine kinase inhibitor for treating Philadelphia chromosome-positive leukemias (ALL, CML), GIST, MDS/MPD, CEL/HES, ASM, and DFSP.
• Zibonta (Botulinum toxin) | زیبونتا Pharmaceutical product containing botulinum neurotoxin for aesthetic applications including wrinkle treatment and facial rejuvenation. Manufactured in-house using proprietary process.
• Lanissa (Tirzepatide) | لانیسا Pharmaceutical product containing tirzepatide for diabetes and endocrinology treatment. New brand added to product portfolio.

Quantifiable outcome

• GMP certification for 3 key production lines in 2018 (bacterial recombinant proteins, vial filling, high-risk oral solids)
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Tehran University of Medical Sciences - Technology Development CentercoreStrategic or Co-development Partner · 1 January 2005Company originated at the Pharmaceutical Products Technology Development Center of Tehran University of Medical Sciences, establishing foundational expertise in pharmaceutical R&D and manufacturing.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Market position

Competitive moat4 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/zistdarudanesh

Compliance12 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zistdaru | زیست دارو